Cargando…
Fomepizole should not be used more liberally in paracetamol overdose
Fomepizole is a promising new treatment for preventing liver injury following paracetamol (acetaminophen) overdose. However, we need robust clinical trials to be performed to demonstrate its effect on clinical outcomes that are important to our patients and important to healthcare providers. Until s...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107630/ https://www.ncbi.nlm.nih.gov/pubmed/36471568 http://dx.doi.org/10.1111/bcp.15596 |
_version_ | 1785026648561680384 |
---|---|
author | Dear, James W. |
author_facet | Dear, James W. |
author_sort | Dear, James W. |
collection | PubMed |
description | Fomepizole is a promising new treatment for preventing liver injury following paracetamol (acetaminophen) overdose. However, we need robust clinical trials to be performed to demonstrate its effect on clinical outcomes that are important to our patients and important to healthcare providers. Until such trials are performed, the toxicology community should learn the lessons from the COVID pandemic—potential novel therapeutic options may be theoretically appealing, but their effectiveness needs to be assessed in robust clinical trials before they are used in clinical practice. |
format | Online Article Text |
id | pubmed-10107630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101076302023-04-18 Fomepizole should not be used more liberally in paracetamol overdose Dear, James W. Br J Clin Pharmacol Clinical Toxicology Pro/Con Debates Series Fomepizole is a promising new treatment for preventing liver injury following paracetamol (acetaminophen) overdose. However, we need robust clinical trials to be performed to demonstrate its effect on clinical outcomes that are important to our patients and important to healthcare providers. Until such trials are performed, the toxicology community should learn the lessons from the COVID pandemic—potential novel therapeutic options may be theoretically appealing, but their effectiveness needs to be assessed in robust clinical trials before they are used in clinical practice. John Wiley and Sons Inc. 2022-12-05 2023-02 /pmc/articles/PMC10107630/ /pubmed/36471568 http://dx.doi.org/10.1111/bcp.15596 Text en © 2022 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Clinical Toxicology Pro/Con Debates Series Dear, James W. Fomepizole should not be used more liberally in paracetamol overdose |
title | Fomepizole should not be used more liberally in paracetamol overdose |
title_full | Fomepizole should not be used more liberally in paracetamol overdose |
title_fullStr | Fomepizole should not be used more liberally in paracetamol overdose |
title_full_unstemmed | Fomepizole should not be used more liberally in paracetamol overdose |
title_short | Fomepizole should not be used more liberally in paracetamol overdose |
title_sort | fomepizole should not be used more liberally in paracetamol overdose |
topic | Clinical Toxicology Pro/Con Debates Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107630/ https://www.ncbi.nlm.nih.gov/pubmed/36471568 http://dx.doi.org/10.1111/bcp.15596 |
work_keys_str_mv | AT dearjamesw fomepizoleshouldnotbeusedmoreliberallyinparacetamoloverdose |